CeriBell (NASDAQ:CBLL) Issues Quarterly Earnings Results

CeriBell (NASDAQ:CBLL) released its earnings results on Tuesday. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07, FiscalAI reports. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The company had revenue of $24.78 million for the quarter, compared to analyst estimates of $23.95 million.

Here are the key takeaways from CeriBell’s conference call:

• Strong top-line growth and solid cash runway — Q4 revenue was $24.8M (+34% YoY) and full-year 2025 revenue was $89.1M (+36%); management guides 2026 revenue of $111M–$115M and ended 2025 with $159M in cash and marketable securities.
• Regulatory and access wins materially expand addressable market — FedRAMP High approval (opens VA system), FDA 510(k) clears for neonatal/pediatric seizure detection, FDA clearance for delirium algorithm, and Breakthrough Device designation for inpatient LVO stroke; management now estimates TAM ≈ $3.5B.
• Commercial traction with room to scale — 647 active hospital accounts (118 net adds in 2025), expansion from ~35 to ~55 territories, and a playbook to drive deeper utilization (currently ~30% penetration) plus a new system-level sales focus expected to accelerate account adds in 2H 2026–2027.
• Rising operating expenses, litigation and margin pressure — FY operating expenses rose 42% to $136.7M and net loss was $53.4M; management expects elevated OpEx (R&D, IP litigation) and mid-80% gross margins in 2026 due to tariff-related cost shifts.
• New product timing limits near-term revenue impact — Neonatal/pediatric full commercial launch targeted for Q2 2026 with modest 2026 contribution (material revenue expected in 2027+); delirium pilots and NTAP pursuit could drive upside but are expected to scale later in 2026–2027.

CeriBell Trading Down 0.5%

CBLL opened at $19.90 on Wednesday. The company has a market cap of $738.29 million, a P/E ratio of -13.18 and a beta of 1.03. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12. The company’s 50 day moving average is $21.26 and its 200-day moving average is $16.17. CeriBell has a 1-year low of $10.01 and a 1-year high of $26.04.

Insiders Place Their Bets

In other news, CFO Scott Blumberg sold 36,000 shares of the stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $21.00, for a total value of $756,000.00. Following the completion of the transaction, the chief financial officer directly owned 118,842 shares in the company, valued at approximately $2,495,682. This represents a 23.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CTO Raymond Woo sold 11,112 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $21.18, for a total value of $235,352.16. Following the sale, the chief technology officer owned 167,317 shares in the company, valued at $3,543,774.06. This represents a 6.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 336,370 shares of company stock worth $6,863,908 over the last 90 days. Insiders own 20.10% of the company’s stock.

Institutional Trading of CeriBell

Several hedge funds and other institutional investors have recently made changes to their positions in CBLL. Sei Investments Co. raised its holdings in CeriBell by 7.1% in the 3rd quarter. Sei Investments Co. now owns 50,454 shares of the company’s stock valued at $580,000 after buying an additional 3,365 shares during the last quarter. Jump Financial LLC acquired a new position in CeriBell in the 2nd quarter valued at approximately $1,476,000. Bank of America Corp DE raised its stake in shares of CeriBell by 1,052.4% during the second quarter. Bank of America Corp DE now owns 72,568 shares of the company’s stock valued at $1,359,000 after acquiring an additional 66,271 shares during the last quarter. PDT Partners LLC lifted its holdings in shares of CeriBell by 13.3% during the fourth quarter. PDT Partners LLC now owns 52,725 shares of the company’s stock worth $1,156,000 after purchasing an additional 6,192 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in shares of CeriBell during the second quarter worth $1,054,000.

Wall Street Analysts Forecast Growth

CBLL has been the topic of a number of analyst reports. TD Cowen reiterated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. BTIG Research reaffirmed a “buy” rating and set a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Canaccord Genuity Group lifted their price objective on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, JPMorgan Chase & Co. cut their target price on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $24.67.

More CeriBell News

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 2025 results beat expectations — EPS of ($0.36) beat the ($0.43) consensus and revenue was $24.78M vs. $23.95M expected, showing topline momentum. Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: FY‑2026 revenue guidance set to $111.0M–$115.0M (midpoint ≈ $113M), which is roughly in line with or slightly above the consensus $112.7M — a modestly constructive signal about growth expectations. CeriBell Press Release / FY2026 Guidance
• Neutral Sentiment: The earnings call transcript and prepared remarks are available for details on product demand, channel dynamics and margin outlook; these may clarify near‑term drivers but did not deliver a clear upside catalyst by themselves. CeriBell Q4 2025 Earnings Call Transcript
• Negative Sentiment: Insider selling: Director Josef Parvizi sold 16,714 shares (and has made multiple recent sales), which can be read as a negative signal on near‑term insider conviction despite his remaining large stake. Insider Selling Report
• Negative Sentiment: Profitability and margins remain weak: the business shows a negative net margin (~63%) and negative ROE, keeping valuation metrics and investor confidence constrained despite the beat. Financials Summary

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.